%0 Journal Article %A KALLE MATTILA %A PIRITA RAANTA %A VALTTERI LAHTELA %A SEPPO PYRHÖNEN %A ILKKA KOSKIVUO %A PIA VIHINEN %T Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha %D 2018 %R 10.21873/anticanres.12999 %J Anticancer Research %P 6393-6397 %V 38 %N 11 %X Background: Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. This study assessed the long-term efficacy of chemoimmunotherapy (bleomycin, vincristine, lomustine and dacarbazine with/without subcutaneous interferon-alpha: BOLD–INF-α) as real-world data in patients with metastatic melanoma not eligible for clinical trials. Patients and Methods: Medical data of 146 patients with stage IV melanoma who had received BOLD/BOLD–INFα regimen during 1991-2010 were analyzed. Results: The median overall survival was 8.9 months (95% confidence intervaI=7.5-10.4 months). The 1-year survival rate was 36%, 2-year 18%, and 5-year 13%. The 5-year survival rates in the M1a, M1b and M1c subgroups were 28%, 10% and 6%, respectively. Overall, 7% (n=11) of the patients were alive at the end of the follow-up. Conclusion: Our study showed similar overall survival among patients with stage IV cutaneous melanoma treated with BOLD/BOLD–INFα as noted previously with chemotherapy. %U https://ar.iiarjournals.org/content/anticanres/38/11/6393.full.pdf